CoChat

Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways

Liu, Xuesong, Han, Edward K., Anderson, Mark, Shi, Yan, Semizarov, Dimitri, Wang, Gang, McGonigal, Thomas, Roberts, Lisa, Lasko, Loren, Palma, Joann, Zhu, Gui-dong, Penning, Thomas, Rosenberg, Saul, Giranda, Vincent L., Luo, Yan, Leverson, Joel, Johnson, Eric F., Shoemaker, Alexander R. · 2009 · Molecular Cancer Research
Cited by 92

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Many established cancer therapies involve DNA-damaging chemotherapy or radiotherapy. Gain of DNA repair capacity of the tumor represents a common mechanism used by cancer cells to survive DNA-damaging therapy. Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that is activated by DNA damage and plays a critical role in base excision repair. Inhibition of PARP represents an attractive approach for the treatment of cancer. Previously, we have described the discovery and characterization of a potent PARP inhibitor, ABT-888. ABT-888 potentiates the activity of DNA-damaging agents such as temozolomide (TMZ) in a variety of preclinical models. We report here the generation of HCT116 cells resistant to treatment with TMZ and ABT-888 (HCT116R cells). HCT116R cells exhibit decreased H2AX phosphorylation in response to treatment with TMZ and ABT-888 relative to parental HCT116 cells. Microarray and Western blot studies indicate that HCT116R cells have decreased PARP-1 and elevated Rad51 expression levels. HCT116R cells are dependent on Rad51 for proliferation and survival, as shown by inhibition of proliferation and induction of apoptosis upon treatment with Rad51 small interfering RNA. In addition, HCT116R cells are more resistant to radiation than the parental HCT116 cells. Our study suggests that cancer cells upregulate the homologous recombination DNA repair pathway to compensate for the loss of base excision repair, which may account for the observed resistance to treatment with TMZ and ABT-888. (Mol Cancer Res 2009;7(10):1686–92)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1541-7786.mcr-09-0299

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 92

Metadata

Authors
Liu, X., Han, E. K., Anderson, M., Shi, Y., Semizarov, D., Wang, G., McGonigal, T., Roberts, L., Lasko, L., Palma, J., Zhu, G.-D., Penning, T., Rosenberg, S., Giranda, V. L., Luo, Y., Leverson, J., Johnson, E. F., & Shoemaker, A. R.
Venue
Molecular Cancer Research
Published
2009-10-23
Volume
7
Issue
10
Pages
1686-1692
ISSN
  • 1541-7786 (ISSN-L)
  • 1557-3125
OpenAlex
W2165087712
Cited by
92
References
11
FWCI
1.79
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-09-0299
The paper
Liu, X., Han, E. K., Anderson, M., Shi, Y., Semizarov, D., Wang, G., McGonigal, T., Roberts, L., Lasko, L., Palma, J., Zhu, G.-D., Penning, T., Rosenberg, S., Giranda, V. L., Luo, Y., Leverson, J., Johnson, E. F., & Shoemaker, A. R. (2009). Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-09-0299

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.